ambien zolpidem

NovaDel initiates clinical trial for insomnia sprayPharmaceutical Business Review - Aug 9, 2006... Zolpidem is the active ingredient found in the number one selling hypnotic, Ambien (zolpidem tartrate), which is marketed by Sanofi-Aventis. ...

Americans May be Relying Too Heavily on Sleeping PillsKansas City infoZine, MO - Aug 8, 2006... The report selected Ambien (zolpidem) as a Best Buy, based primarily on the fact that it is slated to become available as a generic in October. ...

NovaDel Announces Initiation of Clinical Trial of Zolpidem Oral ...PharmaLive.com (press release), PA - Aug 8, 2006... Ambien(R) (zolpidem tartrate), is a non-benzodiazepine hypnotic of the imidazopyridine class that is indicated for the treatment of short-term insomnia. ...

NovaDel Pharma Reports Beginning Of Clinical Trial Of Zolpidem ...Trading Markets, CA - Aug 8, 2006... formulation of zolpidem oral spray. Zolpidem is the active ingredient found in hypnotic Ambien. The trial, which is being conducted ...

Myth or FactWebMD - Aug 4, 2006... 6. The newer BzRAs - such as Ambien® (zolpidem), Sonata® (zaleplon), and Lunesta™ (eszopiclone) - are not yet widely prescribed. ...

NovaDel Begins Trail for Oral Spray Sleep AidBusiness New Jersey (subscription), NJ - Aug 8, 2006... its zolpidem oral spray. Zolpidem is the active ingredient of popular sleep medication Ambien. Pharmaceutical giant Sanofi-Aventis ...

Diverse challenges await generics industryPipelineReview.com (press release), Spain - Aug 7, 2006... are also expected to become subject to generic competition, including Pfizer's Zoloft (sertraline), Sanofi-Aventis' Ambien (zolpidem), GlaxoSmithKline's Zofran ...

Sanofi raises earnings forecasts on solid Q2Pharma Times (subscription), UK - Aug 2, 2006... drug Lantus (insulin glargine) and solid performances from the antithrombotic Lovenox (enoxaparin) and Sanofi's Stilnox/Ambien (zolpidem) sleeping pill ...

New Data Support Long-Term Use Of AMBIEN CRTM (zolpidem Tartrate ...Medical News Today (press release), UK - Jul 14, 2006Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) today announced results from a study that demonstrated AMBIEN CR is well-tolerated and ...

New Data Support Long-Term Use of Zolpidem Tartrate Extended ...DG News - Jul 12, 2006BRIDGEWATER, NJ -- July 12, 2006 -- Sanofi-aventis today announced results from a study that demonstrated Ambien CR (zolpidem tartrate extended release tablets ...